Suzhou Fengbei Biotech Stock Co., Ltd. (SHA:603334)

SHA:603334 Revenue

Suzhou Fengbei Biotech Stock had revenue of 1.11B CNY in the quarter ending March 31, 2026, with 50.02% growth. This brings the company's revenue in the last twelve months to 3.61B, up 64.78% year-over-year. In the year 2025, Suzhou Fengbei Biotech Stock had annual revenue of 3.17B with 62.77% growth.

• Revenue (ttm): 3.61B
• Revenue Growth: +64.78%
• P/S Ratio: 1.97
• Revenue / Employee: 9.15M
• Employees: 395
• Market Cap: 7.13B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	3.17B	1.22B	62.77%
Dec 31, 2024	1.95B	220.23M	12.75%
Dec 31, 2023	1.73B	19.09M	1.12%
Dec 31, 2022	1.71B	413.11M	31.89%
Dec 31, 2021	1.30B	505.78M	64.04%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

May 11, 2026

Data Sources Report a data error